Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 27

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 27
---
 the Iris Class A Shares of such holder for

<div align='center'>v</div>

TABLE OF CONTENTS

redemption not later than 5:00 p.m. Eastern Time on the date that is two Business Days prior to the date of the Special Meeting.

“ RRA ” means that certain Amended and Restated Registration Rights Agreement, to be entered into in connection with the consummation of the Business Combination, by and among ParentCo, Sponsor, Cantor, certain former members of Liminatus and the PIPE Investor.

“ Securities Act ” means the Securities Act of 1933, as amended.

“ SPAC Merger ” means the merger of SPAC Merger Sub with and into Iris, with Iris being the surviving corporation in the merger and a wholly-owned subsidiary of ParentCo.

“ SPAC Merger Sub ” means SPAC Merger Sub, Inc., a Delaware corporation.

“ SPAC Share Redemptions ” means the election of an eligible holder of Iris Class A Shares to redeem all or a portion of such holder’s Iris Class A Shares.

“ SPAC Surviving Subsidiary ” means surviving corporation of the SPAC Merger.

“ Special Meeting ” means the Special Meeting of stockholders of Iris that is the subject of this proxy statement/prospectus.

“ Sponsor ” means Iris Acquisition Holdings LLC, a Delaware limited liability company.

“ Sponsor Forfeiture Agreement ” means the agreement between the Sponsor and Iris and Liminatus, pursuant to which the Sponsor has agreed to forfeit 4,177,778 of its Private Placement Warrants at closing, attached to this proxy statement/prospectus as Annex F .

“ Sponsor Support Agreement ” means that certain Sponsor Support Agreement, dated November 30, 2022, by and among Iris, Liminatus, and Sponsor, attached to this proxy statement/prospectus as Annex D.

“ TDT ” means Targeted Diagnostics & Therapeutics, Inc.

“ TDT License ” means the License Agreement with an effective date of June 10, 2018, by and between TDT, and the Company, granting exclusive worldwide rights to Develop and Commercialize the CAR T Product in the Field and non-exclusive worldwide rights to Develop and Commercialize the Companion Diagnostics to the CAR T Products in the Field (such italicized terms bearing the meanings ascribed to them in the TDT License).

“ TJU License ” means the Amended and Restated License Agreement dated as of January 1, 1999, by and between